Tandem Diabetes Care’s Executive Buys Back 77 Shares Amid 40% Stock Slide: Insider Confidence Signals “Buy the Dip” Strategy
Mark David’s recent 77‑share buy at $18.47 shows executive confidence in Tandem Diabetes Care’s future despite a 40% drop, offering investors a cautious‑optimism signal amid market volatility.
6 minutes to read

